NIKKEI 225
27,606.46 -79.01 (-0.29%) HANG SENG
21,283.52 -15.18 (-0.07%) CRUDE OIL
78.32 +1.18 (+1.53%) GOLD FUTURES
1,892.10 +7.30 (+0.39%) DOW
34,054.60 -102.09 (-0.30%) BTC-GBP
18,969.46 -102.70 (-0.54%)
Moderna, Inc. (MRNA)
| Previous close | 171.06 |
| Open | 169.33 |
| Bid | 165.66 x 900 |
| Ask | 165.74 x 3100 |
| Day's range | 165.10 - 170.39 |
| 52-week range | 115.03 - 217.25 |
| Volume | |
| Avg. volume | 4,976,447 |
| Market cap | 63.618B |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 207.29 |
- Zacks
Moderna (MRNA) Gains But Lags Market: What You Should Know
Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session.
- Reuters
Drug companies face COVID cliff in 2023 as sales set to plummet
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
- Motley Fool
3 No-Brainer Growth Stocks to Buy in 2023
In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.
